Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Pharmaceutical companyLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field. in JapanLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field.. FDA records under its name, each linked to the record. See the Kyowa Kirin group view.
As of Nov 15, 2026, FDA's public records list Kyowa Kirin with 4 drug applications.
Drug applications: 4
Records by Year
Drug approvals, 510(k) clearances, recalls and letters, 2017 to 2026 to date
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
02017Records0
220182018Records2vs 2017+2
12019Records1vs 2018−1
020202020Records0vs 2019−1
02021Records0vs 2020+0
020222022Records0vs 2021+0
02023Records0vs 2022+0
020242024Records0vs 2023+0
02025Records0vs 2024+0
020262026 to dateRecords0
Latest Records
Newest first across sources; each opens the record
FDA's databases did not answer. Reload in a moment.
Payments to Doctors (Open Payments)
What 3 reporting entities in this group reported paying US doctors and teaching hospitals each year; see every company
2025: $19.2MGeneral $2.1M · Research $17.2M
2024: $11.9MGeneral $2.5M · Research $9.3M
2023: $6.2MGeneral $2.5M · Research $3.7M
2022: $5.1MGeneral $2.0M · Research $3.1M
2021: $2.4MGeneral $1.5M · Research $0.9M
2020: $4.5MGeneral $1.3M · Research $3.2M
2019: $4.7MGeneral $1.0M · Research $3.6M
Orphan Designations (FDA)
6 designations since 1983, 4 approved for the designated use, matched by the sponsor's name; see all orphan designations
CrysvitaTreatment of tumor-induced osteomalacia (TIO) syndrome · Jun 15, 2017 · approved Jun 18, 2020
mogamulizumabTreatment of adult T-cell leukemia/lymphoma (ATLL). · Jul 14, 2011
POTELIGEOTreatment of patients with cutaneous T-cell lymphoma. · Nov 2, 2010 · approved Aug 8, 2018
mogamulizumabTreatment of peripheral T-cell lymphoma. · Nov 2, 2010
CrysvitaTreatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets) · Dec 14, 2009 · approved Apr 17, 2018
CrysvitaTreatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets) · Dec 14, 2009 · approved Sep 27, 2019
Medicines Authorised in the EU (EMA)
2 medicines, 2 of them new active substances, matched by the authorisation holder's name; see all EU approvals
PoteligeoNew substance · mogamulizumab · Nov 22, 2018
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata.How this page is built
